Sagimet Biosciences (SGMT) Change in Accured Expenses (2022 - 2026)

Sagimet Biosciences' Change in Accured Expenses history runs 5 years deep, the most recent figure standing at $637000.0 for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 81.21% year-over-year to $637000.0; the TTM figure through Mar 2026 stood at -$1.8 million (down 155.87% YoY), while the FY2025 annual figure was $929000.0, up 202.43% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $637000.0, up from -$4.0 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $3.4 million in Q1 2025, with the low at -$4.0 million in Q4 2025.
• The 5-year median for Change in Accured Expenses is $320000.0 (2023), against an average of $55266.7.
• Peak annual rise in Change in Accured Expenses reached 533.5% in 2025, while the deepest fall reached 994.82% in 2025.
• Sagimet Biosciences' Change in Accured Expenses stood at -$1.0 million in 2022, then soared by 131.84% to $320000.0 in 2023, then soared by 38.75% to $444000.0 in 2024, then slumped by 994.82% to -$4.0 million in 2025, then surged by 116.03% to $637000.0 in 2026.
• Business Quant data shows SGMT's Change in Accured Expenses at $637000.0 in Q1 2026, -$4.0 million in Q4 2025, and $1.6 million in Q3 2025.